ストックスクリーナーアプリを入手
133.29
1.90%
-2.58
プレマーケット:
133.39
0.10
+0.08%
前日終値:
$135.87
開ける：
$136.18
24時間の取引高:
6.07M
Relative Volume:
0.88
時価総額：
$165.44B
収益：
$29.45B
当期純損益:
$8.51B
株価収益率:
19.65
EPS:
6.7823
ネットキャッシュフロー:
$9.46B
1週間 パフォーマンス:
-5.10%
1か月 パフォーマンス:
-2.86%
6か月 パフォーマンス:
+7.42%
1年 パフォーマンス:
+27.76%
1日の値動き範囲:
$132.22
$136.34
1週間の範囲:
$132.22
$140.96
52週間の値動き範囲:
$93.37
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Compare GILD vs LLY, JNJ, ABBV, AZN, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
133.29 | 165.44B | 29.45B | 8.51B | 9.46B | 6.7823 |
LLY
Lilly Eli Co
|
903.02 | 806.72B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
226.16 | 544.73B | 96.36B | 21.04B | 19.70B | 8.6488 |
ABBV
Abbvie Inc
|
205.12 | 362.81B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
195.78 | 303.62B | 58.80B | 10.24B | 8.98B | 3.2788 |
NVS
Novartis Ag Adr
|
147.97 | 282.35B | 54.72B | 14.02B | 15.32B | 7.1855 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-10 | 開始されました | Jefferies | Buy |
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-02-11 | 繰り返されました | Needham | Buy |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-08-19 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | アップグレード | Truist | Hold → Buy |
| 2025-07-25 | アップグレード | Needham | Hold → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
| 2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 繰り返されました | Maxim Group | Buy |
| 2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-02-22 | ダウングレード | Truist | Buy → Hold |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
Gilead Sciences Inc. stock outperforms competitors despite losses on the day - MarketWatch
Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now? - TradingView
Release of 2025 impact report weighs on Gilead Sciences stock amid oversold momentum signals - Traders Union
Gilead Sciences Deploys $16 Billion in 60 Days: Is GILD Stock Undervalued for 2026? - TIKR.com
7,568 Shares in Gilead Sciences, Inc. $GILD Acquired by Ticino Wealth - MarketBeat
Gilead, Arcus tumble again in TIGIT, triggering 2 trial culls - BioSpace
Gilead Sciences : Publishes 2025 Responsible Business and Impact Report, Highlighting Momentum Toward 2030 Ambitions - marketscreener.com
Arcus pulls another TIGIT trial as Gilead steps back - The Pharma Letter
Zacks Research Predicts Lower Earnings for Gilead Sciences - MarketBeat
Gilead Sciences, Inc. (GILD) Stock Analysis: A Healthcare Giant with a 15% Upside Potential - DirectorsTalk Interviews
Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors - Yahoo Finance
Lobbying Update: $3,190,000 of GILEAD SCIENCES INC lobbying was just disclosed - Quiver Quantitative
Gilead Sciences: Why I'm Tempted To Sell Ahead Of Q1 EarningsBut Won't (NASDAQ:GILD) - Seeking Alpha
Leerink cuts Arcus Biosciences stock price target on Gilead collaboration end - Investing.com Canada
Gilead Sciences stock edges lower as company discusses expanding oncology reach at AACR26 - Traders Union
Arcus halts Gilead-partnered late-stage trial (RCUS:NYSE) - Seeking Alpha
Arcus Ends Key Lung Cancer Trials in Gilead Partnership Reset - TipRanks
Arcus Biosciences ends STAR-121 lung cancer study and updates Gilead collaboration - Investing.com
Arcus Biosciences Incdiscontinues phase 3 star-121 study with Gilead due to futility - marketscreener.com
Zurcher Kantonalbank Zurich Cantonalbank Purchases 19,741 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Stake Lowered by Miller Howard Investments Inc. NY - MarketBeat
Gilead Sciences (NASDAQ:GILD): A Value Screen Candidate with Strong Profitability - ChartMill
Gilead Sciences to buy clinical-stage biotech Tubulis for up to $5 billion - MSN
Gilead Sciences, Inc. (GILD) is a trending stock: Facts to know before betting on it - MSN
Gilead Deepens Oncology Reach And HIV Prevention With Arcellx And Lenacapavir - Yahoo Finance
Gilead Sciences, Inc. $GILD Shares Acquired by AE Wealth Management LLC - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by GF Fund Management CO. LTD. - MarketBeat
Gilead Sciences, Inc. $GILD Position Raised by Asset Management One Co. Ltd. - MarketBeat
Wall Street Analysts Are Neutral on Top Healthcare Picks - The Globe and Mail
Citi Raises Gilead (GILD) Price Target Ahead of Q1 Biopharma Preview - Insider Monkey
Jim Cramer on Gilead Sciences: “I’d Hold On to It” - Insider Monkey
Gilead Sciences stock edges lower as research teams attend AACR26 to advance cancer therapies - Traders Union
Gilead (GILD) Extends Tender Offer for Arcellx (ACLX) to April 2 - GuruFocus
Gilead extends Arcellx tender offer again - MSN
Gilead Sciences (NASDAQ:GILD) Given New $130.00 Price Target at The Goldman Sachs Group - MarketBeat
Morgan Stanley Adjusts Gilead Sciences, Inc. (GILD) Outlook Ahead of Q1 Earnings - Insider Monkey
Goldman Sachs Adjusts Gilead Sciences Price Target to $130 From $125, Maintains Neutral Rating - Moomoo
Gilead extends Arcellx tender offer again (GILD:NASDAQ) - Seeking Alpha
Gilead Sciences (NASDAQ: ACLX) offers $115 per share plus CVR; deadline extended - Stock Titan
Gilead Sciences patents new GTPase KRAS G12D inhibitors - BioWorld News
Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $155 From $115, Maintains Overweight Rating - Moomoo
Gilead extends Arcellx tender offer to April 27 - Investing.com
Gilead extends Arcellx tender offer to April 27 By Investing.com - Investing.com India
Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer - Business Wire
Mirae Asset Global Investments Co. Ltd. Grows Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gene Transplant Market Is Going to Boom | Novartis • Gilead Sciences • Kite Pharma • Bluebird Bio - openPR.com
Farther Finance Advisors LLC Raises Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Stock Holdings Lowered by Assetmark Inc. - MarketBeat
GILD Stock Price, Quote & Chart | GILEAD SCIENCES INC (NASDAQ:GILD) - ChartMill
Insider Sell: Andrew Dickinson Sells Shares of Gilead Sciences I - GuruFocus
Insider Selling: Gilead Sciences (NASDAQ:GILD) Insider Sells $422,880.00 in Stock - MarketBeat
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
Gilead Sciences Inc (GILD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Mercier Johanna | Chief Comm & Corp Aff Officer |
Apr 15 '26 |
Sale |
140.96 |
3,000 |
422,880 |
128,779 |
2.57%
大文字化:
|
ボリューム (24 時間):